A081801 (sub study A151216)

The purpose of this study is to compare disease free survival when adding immunotherapy to initial chemotherapy vs immunotherapy only in maintenance therapy. You must be diagnosed with stage 2 or stage 3 non-small cell lung cancer (NSCLC).
Contact phone
Tracy Bellefeuil | 517.364.2835
Contact email
Principal investigator
Dr. Gordan Srkalovic, MD, PhD
Trial Category
Trial SubCategory
Non-Small Cell Lung